Search results
This startup uses overseas freelancers to help Americans find Adderall and Ozempic
Quartz· 2 days agoA startup is working to help Americans navigate ongoing shortages of highly-coveted drugs like...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 6 days agoRecap of the Week’s Most Important Stories Lilly’s CFO Departs: Lilly’s executive vice president and...
Chutes & Ladders—Sanofi research head Frank Nestle says au revoir
FierceBiotech· 6 days agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...
European Midday Briefing: Stocks, Euro Hit by European Political Upheaval
Morningstar· 3 days agoEuropean stocks fell on Monday after European elections resulted in strong gains for right-wing Euroskeptic parties, prompting Emmanuel Macron to call a snap election in France. The main takeaways ...
10 Best ETFs To Buy and Hold for Long-Term Growth
GoBankingRates via AOL· 1 day agoIf you're a long-term investor looking to diversify your growth portfolio, there are a number of exchange-traded funds that can help you reach your...
Another Approach To Checkpoint Inhibitors: Targeting Receptors
Forbes· 3 days agoAn alternative to PD-1 targeting cancer therapies, PD-L1 checkpoint inhibitors boost antitumor...
JD Supra: Better Health Care Newsletter
JD Supra· 7 days agoFederal officials have capped the cost of insulin at $35 a month. For now, that gives relief only to patients 65 and older covered by Medicare. Big Pharma in recent years has flouted that charitable intent.
Experts Focus on Quality-of-Life Data in Prostate Cancer
Medscape· 2 days agoSeveral trials presented at ASCO 2024 explored strategies to improve quality of life in patients with prostate cancer.
Ongoing Efforts to Expand Kidney Donor Pool Seem Mostly Safe
Medscape· 1 day agoLiving donors had a similar risk for hypertension and albuminuria after donation as nondonors, and...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 6 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.